Pharvaris Valuation Multiples

Pharvaris Overview

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Founded

2015

HQ

Employees

108

Website

pharvaris.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($190M)

EV

$1B

Valuation Multiples

Multiples.vc

Start free trial

Pharvaris Financials

Pharvaris reported last 12-month revenue of — and negative EBITDA of ($190M).

In the same LTM period, Pharvaris generated — in gross profit, ($190M) in EBITDA losses, and had net loss of ($188M).

Pharvaris P&L

In the most recent fiscal year, Pharvaris reported revenue of — and EBITDA of ($154M).

Pharvaris expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pharvaris Stock Performance

Pharvaris has current market cap of $2B, and enterprise value of $1B.

Pharvaris' stock price is $26.66.

Pharvaris Valuation Multiples

Pharvaris trades at (7.1x) EV/EBITDA.

Pharvaris Financial Valuation Multiples

As of March 21, 2026, Pharvaris has market cap of $2B and EV of $1B.

Equity research analysts estimate Pharvaris' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pharvaris has a P/E ratio of (9.2x).

Pharvaris Margins & Growth Rates

Pharvaris' revenue in the last fiscal year grew by —.

Pharvaris' revenue per employee in the last FY averaged $0.0M.

Pharvaris Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Pharvaris M&A Activity

Pharvaris acquired XXX companies to date.

Last acquisition by Pharvaris was on XXXXXXXX, XXXXX. Pharvaris acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pharvaris Investment Activity

Pharvaris invested in XXX companies to date.

Pharvaris made its latest investment on XXXXXXXX, XXXXX. Pharvaris invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).